The clinical trial investigates the efficacy of the GLP-1 analogue Victoza® (liraglutide) in treating plaque psoriasis, a condition with significant unmet medical need. Given the increasing prevalence of psoriasis and the limitations of current therapies, successful outcomes could position liraglutide as a novel treatment option, potentially expanding its market beyond diabetes management. The competitive landscape includes biologics and systemic therapies, necessitating a thorough analysis of market entry strategies and pricing models. Diligence should focus on patient recruitment, adherence to eligibility criteria, and the robustness of outcome measures, particularly PASI and DLQI scores, which are critical for regulatory approval and market acceptance.